Showing 5981-5990 of 9451 results for "".
Update on Topical Acne Therapy for Adult Women
https://practicaldermatology.com/topics/general-topics/update-on-topical-acne-therapy-for-adult-women/19166/Diane Berson, MD, FAAD discusses the approach to management of acne in the adult female patient, emphasizing the role of vehicle to affect the patient experience, promote adherence, and optimize outcomes. Bonus Material: Hormonal Therapy for Female Acne Bonus Material: Procedures for Adult Female APromising Therapies on the Atopic Dermatitis Horizon
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37178/Justin Marson, MD, Chief Resident 2024-25 in the Department of Dermatology at SUNY Downstate Health Science University, previews important potential developments in the atopic dermatitis pipeline"Atopic Dermatitis in Diverse Skin Tones" Drs. Shahriari and Bhutani
https://practicaldermatology.com/youngmd-connect/ymdc-workshops/atopic-dermatitis-in-diverse-skin-tones-drs-shahriari-and-bhutani/24542/Drs. Mona Shahriari and Tina Bhutani provide a comprehensive overview of managing atopic dermatitis (AD) in patients with skin of color, addressing unique challenges and considerations. To access the full video and more, join YoungMD Connect member for free 90-day trial with code Free90. Continue leMechanisms of Action for IL-17 Inhibition in Treating Psoriasis and Hidradenitis Suppurativa
https://practicaldermatology.com/programs/practical-dermatology-il-17-journal-club/mechanisms-of-action-for-il-17-inhibition-in-treating-psoriasis-and-hidradenitis-suppurativa/48808/Practical Dermatology Editorial Board member Jason E. Hawkes, MD, MS, FAAD, joins Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss articles from the Journal of Clinical Medicine and Clinics in Dermatology on how IL-17 inhibition is effective in treating psoriasis and hidradenitis suppurativa,The Significance of Tolerability and Persistent Efficacy in Pediatric Atopic Dermatitis
https://practicaldermatology.com/programs/practical-dermatology-updates-in-atopic-dermatitis/program-name/57285/Lawrence Eichenfield, MD, discusses evolving topical treatment options for pediatric atopic dermatitis, with a focus on tolerability, efficacy, and persistent disease control.Can Treating Atopic Dermatitis Restore Growth in Children?
https://practicaldermatology.com/programs/practical-dermatology-type-ii-inflammation-journal-club/can-treating-atopic-dermatitis-restore-growth-in-children/50933/Practical Dermatology Editorial Board members Natasha Mesinkovska, MD, PhD, and Christopher Bunick, MD, FAAD, discuss the Journal of the American Academy of Dermatology article “Dupilumab, atopic dermatitis, and linear growth: Navigating beyond association to mechanism and intervention,” which featuPractical Dermatology Roundtable: The Role of Adjuvant Skin Cleansing and Moisturizing in Treating Psoriasis and Other Inflammatory Diseases, Ch. 7
https://practicaldermatology.com/programs/the-practical-dermatology-roundtable/practical-dermatology-roundtable-the-role-of-adjuvant-skin-cleansing-and-moisturizing-in-treating-psoriasis-and-other-inflammatory-diseases-ch-7/56875/In the seventh installment of this eight-part series, host Ted Lain, MD, MBA, FAAD, and guests Zoe Diana Draelos, MD, and Firas George Hougeir, MD, FAAD, shift to clinical applications, including maintenance therapy, steroid-sparing strategies, and opportunities for future research.1 Draelos Z, HouDWTV Extra: Raising Awareness of GPP
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-raising-awareness-of-gpp/56366/Shannon Trotter, DO, discusses the importance of awareness of generalized pustular psoriasis (GPP) and targeting IL-36, as well as GPP Awareness Day in August.Dermwire TV: Ruxolitinib Cream 1.5% Effective for AD Improvement, Stapokibart Shows Promise
https://practicaldermatology.com/videos/dermwire-tv/dermwire-tv-ruxolitinib-cream-15-effective-for-ad-improvement-stapokibart-shows-promise/49101/This episode highlights new research showing ruxolitinib cream 1.5% providing itch relief and broader atopic dermatitis (AD) improvement, as well as a post-hoc analysis finding safety and efficacy for stapokibart in elderly adults with AD; and Excellergy executives discuss how recent research validaOrigins of AD: Recent Advances
https://practicaldermatology.com/issues/april-2025/origins-of-ad-recent-advances/35586/This paper reviews a study by Yadev et al. and further investigates the role of transient receptor potential ankyrin 1 (TRPA1) in the pathogenesis of atopic dermatitis (AD).